A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

References

• Danish Neuro-Oncology Group. 2009 Annual Report of the Danish Neuro-Oncology Registry.
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–96.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58–62.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009;11:80–91.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, . Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009;48:52–8.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27: 4733–40.
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572–8.
   PubMed Web of Science ®Google Scholar
• Jain RK, di TE, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610–22.
   PubMed Web of Science ®Google Scholar
• Macdonald DR,, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, . Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, . Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91: 329–36.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, . Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14: 7068–73.
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van den BM, Stupp R. Bevacizumab and recurrent malignant gliomas: A European perspective. J Clin Oncol 2010;28:e188–9.
   PubMed Web of Science ®Google Scholar
• Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, . Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143–51.
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, . Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271–8.
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, . Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118:585–94.
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, . Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–67.
   PubMed Web of Science ®Google Scholar
• Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, . Bevacizumab for recurrent ependymoma. Neurology 2009;73:1677–80.
   PubMed Web of Science ®Google Scholar